ES2055607T3 - Composiciones farmaceuticas estables que contienen un factor de crecimiento de fibroblastos. - Google Patents

Composiciones farmaceuticas estables que contienen un factor de crecimiento de fibroblastos.

Info

Publication number
ES2055607T3
ES2055607T3 ES91912379T ES91912379T ES2055607T3 ES 2055607 T3 ES2055607 T3 ES 2055607T3 ES 91912379 T ES91912379 T ES 91912379T ES 91912379 T ES91912379 T ES 91912379T ES 2055607 T3 ES2055607 T3 ES 2055607T3
Authority
ES
Spain
Prior art keywords
growth factor
fibroblast growth
pharmaceutical compositions
compositions containing
stable pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912379T
Other languages
English (en)
Inventor
Marco Adami
Casa Rosanna Dalla
Luciano Gambini
Roberto Magrini
Rosaria Mariani
Giovanni Perrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Application granted granted Critical
Publication of ES2055607T3 publication Critical patent/ES2055607T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA FORMULACION LIOFILIZADA ESTABLE DE UN FACTOR DE CRECIMIENTO DE FIBROBLASTO (FGF) COMPRENDE EL FGF, UN AGENTE DE ABULTAMIENTO Y BIEN (A) UNA SAL DE METAL ALCALINO DE UNA CELULOSA CARBOXILICA O (B) UNA CISTEINA Y ESTER DE ACIDO GRASO SORBITAN DE POLIOXIETILENO.
ES91912379T 1990-07-18 1991-07-16 Composiciones farmaceuticas estables que contienen un factor de crecimiento de fibroblastos. Expired - Lifetime ES2055607T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909015824A GB9015824D0 (en) 1990-07-18 1990-07-18 Stable pharmaceutical compositions containing a fibroblast growth factor

Publications (1)

Publication Number Publication Date
ES2055607T3 true ES2055607T3 (es) 1994-08-16

Family

ID=10679294

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912379T Expired - Lifetime ES2055607T3 (es) 1990-07-18 1991-07-16 Composiciones farmaceuticas estables que contienen un factor de crecimiento de fibroblastos.

Country Status (8)

Country Link
EP (1) EP0539408B1 (es)
JP (1) JP3100058B2 (es)
AU (1) AU659997B2 (es)
CA (1) CA2087430A1 (es)
DE (1) DE69101784T2 (es)
ES (1) ES2055607T3 (es)
GB (1) GB9015824D0 (es)
WO (1) WO1992001442A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
AU659723B2 (en) * 1992-02-14 1995-05-25 Kaken Pharmaceutical Co., Ltd. Remedy for airway diseases
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CA2280130C (en) * 1997-02-05 2007-12-18 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
JP4549529B2 (ja) * 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
US7754686B2 (en) 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
CN117205162B (zh) * 2023-09-12 2024-06-25 上海腾瑞制药股份有限公司 一种重组人酸性成纤维细胞生长因子冻干制剂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
CN1032081A (zh) * 1987-09-15 1989-03-29 米德公司 表面含有热引发剂的接受片
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof

Also Published As

Publication number Publication date
AU8109491A (en) 1992-02-18
AU659997B2 (en) 1995-06-08
GB9015824D0 (en) 1990-09-05
DE69101784D1 (de) 1994-05-26
DE69101784T2 (de) 1994-08-04
CA2087430A1 (en) 1992-01-19
EP0539408A1 (en) 1993-05-05
JPH05508640A (ja) 1993-12-02
WO1992001442A1 (en) 1992-02-06
JP3100058B2 (ja) 2000-10-16
EP0539408B1 (en) 1994-04-20

Similar Documents

Publication Publication Date Title
ES2183023T3 (es) Composicion farmaceutica estabilizada con un agente basico.
PT1197221E (pt) Preparacoes de g-csf estabilizadas a longo prazo.
DE59305359D1 (de) Desodorierende kosmetische zubereitungen mit einem gehalt an di- oder triglycerinestern
NZ512792A (en) Stable liquid interferon beta formulations
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
AR002932A1 (es) Solucion acuosa de interferon
AU628768B2 (en) Stabilized solutions of psychotropic agents
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
EP1004305A4 (en) STABILIZED COMPOSITIONS CONTAINING BENZIMIDAZOLE
ES2055607T3 (es) Composiciones farmaceuticas estables que contienen un factor de crecimiento de fibroblastos.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
MX9700374A (es) Formulaciones acuosas de risperidona.
DK605786D0 (da) Stabiliserede human-vaevsplasminogenaktivator-praeparater
ES2098672T3 (es) Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3.
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
DK0460062T3 (da) Huperzin A-analoger
MY132911A (en) Clear, injectable solution of an anesthetic compound
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
IT1265074B1 (it) Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
ES2091260T3 (es) Procedimiento para la preparacion de piridin-2,3-dicarboxilato dialquilico y derivados del mismo a partir de diclorosuccinato dialquilico.
PT91468A (pt) Processo para a preparacao de um novo antibiotico mersacidina e de composicoes farmaceuticas que o contem
BR9912706A (pt) Composições farmacêuticas contendo ibuprofeno e domperidona
NO982229D0 (no) Svovelholdige di-tert-butylfenol-forbindelser anvendbare som antiinflammatoriske midler
FI913909A0 (fi) t-PA pro:n stabilointi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539408

Country of ref document: ES